{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:08Z","timestamp":1788240908384,"version":"build-2803163510"},"reference-count":121,"publisher":"Walter de Gruyter GmbH","issue":"3-4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Psoriasis, recognized as a chronic inflammatory skin disorder, disrupts immune system functionality. Global estimates by the World Psoriasis Day consortium indicate its impact on approximately 130 million people, constituting 4 to 5 percent of the worldwide population. Conventional drug delivery systems, mainly designed to alleviate psoriasis symptoms, fall short in achieving targeted action and optimal bioavailability due to inherent challenges such as the drug\u2019s brief half-life, instability, and a deficiency in ensuring both safety and efficacy. Liposomes, employed in\u00a0drug delivery systems, emerge as highly promising carriers for augmenting the therapeutic efficacy of topically applied drugs. These small unilamellar vesicles demonstrate enhanced penetration capabilities, facilitating drug delivery through the stratum corneum layer of skin. This comprehensive review article illuminates diverse facets of\u00a0liposomes as a promising drug delivery system to treat psoriasis. Addressing various aspects such as formulation strategies, encapsulation techniques, and targeted delivery, the review underscores the potential of liposomes in enhancing the efficacy and specificity of psoriasis treatments.<\/jats:p>","DOI":"10.1515\/znc-2024-0118","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T13:24:53Z","timestamp":1721654693000},"page":"41-60","source":"Crossref","is-referenced-by-count":8,"title":["Advancing psoriasis drug delivery through topical liposomes"],"prefix":"10.1515","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4085-8936","authenticated-orcid":false,"given":"Devesh U.","family":"Kapoor","sequence":"first","affiliation":[{"name":"Dr. Dayaram Patel Pharmacy College , Bardoli 394601 , Gujarat , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Garg","sequence":"additional","affiliation":[{"name":"Asian College of Pharmacy , Rajasthan University of Health Sciences , Udaipur , Rajasthan 313001 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Technology Management , SVKM\u2019s Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University , Green Industrial Park, TSIIC, 509301 , Jadcherla , Hyderabad , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Gaur","sequence":"additional","affiliation":[{"name":"Rajasthan Pharmacy College , Rajasthan University of Health Sciences , Jaipur 302026 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Sharma","sequence":"additional","affiliation":[{"name":"Institute of Pharmacy , Assam Don Bosco University , Tapesia , Assam 782402 , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-4541","authenticated-orcid":false,"given":"Bhupendra G.","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Shree S. K. Patel College of Pharmaceutical Education and Research , Ganpat University , Kherva 384012 , India"},{"name":"Faculty of Pharmacy , Silpakorn University , Nakhon Pathom 73000 , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2025022817345924465_j_znc-2024-0118_ref_001","doi-asserted-by":"crossref","unstructured":"Unissa, R, Kumar, PM, Pasha, M, Begum, S, Maheswari, B. Psoriasis: a comprehensive review. Asian J Res Pharm Sci 2019;9:29\u201338. https:\/\/doi.org\/10.5958\/2231-5659.2019.00005.5.","DOI":"10.5958\/2231-5659.2019.00005.5"},{"key":"2025022817345924465_j_znc-2024-0118_ref_002","doi-asserted-by":"crossref","unstructured":"Singh, N, Sondhi, S, Jindal, S, Pandit, V, Ashawat, MS. Treatment and management for patients with mild to severe psoriasis: a review. Asian J Pharm Res 2020;10:286\u201392. https:\/\/doi.org\/10.5958\/2231-5691.2020.00049.0.","DOI":"10.5958\/2231-5691.2020.00049.0"},{"key":"2025022817345924465_j_znc-2024-0118_ref_003","doi-asserted-by":"crossref","unstructured":"Ten Bergen, LL, Petrovic, A, Aarebrot, AK, Appel, S. Current knowledge on autoantigens and autoantibodies in psoriasis. Scand J Immunol 2020;92:e12945. https:\/\/doi.org\/10.1111\/sji.12945.","DOI":"10.1111\/sji.12945"},{"key":"2025022817345924465_j_znc-2024-0118_ref_004","doi-asserted-by":"crossref","unstructured":"Boca, AN, Ilies, RF, Vesa, S, Pop, R, Tataru, AD, Buzoianu, AD. The first nation-wide study revealing epidemiologic data and life quality aspects of psoriasis in Romania. Exp Ther Med 2019;18:900\u20134. https:\/\/doi.org\/10.3892\/etm.2019.7652.","DOI":"10.3892\/etm.2019.7652"},{"key":"2025022817345924465_j_znc-2024-0118_ref_005","doi-asserted-by":"crossref","unstructured":"Nick, D, Mahil, SK, Capon, F, Smith, CH, Simpson, MA, Barker, JN. Psoriasis and genetics. Acta Derm Venereol 2020;100. https:\/\/doi.org\/10.2340\/00015555-3384.","DOI":"10.2340\/00015555-3384"},{"key":"2025022817345924465_j_znc-2024-0118_ref_006","unstructured":"Michalek, IM, Loring, B, John, SM. Global report on psoriasis. Geneva, Switzerland: World Health Organization; 2016."},{"key":"2025022817345924465_j_znc-2024-0118_ref_007","doi-asserted-by":"crossref","unstructured":"Hay, SI, Abajobir, AA, Abate, KH, Abbafati, C, Abbas, KM, Abd-Allah, F, et al.. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1260\u2013344. https:\/\/doi.org\/10.1016\/s0140-6736(17)32130-x.","DOI":"10.1016\/S0140-6736(17)32130-X"},{"key":"2025022817345924465_j_znc-2024-0118_ref_008","doi-asserted-by":"crossref","unstructured":"Sch\u00f6n, MP, Dagmar, W\u2010T. Current developments and perspectives in psoriasis. J Dtsch Dermatol Ges 2023;21:363\u201372.","DOI":"10.1111\/ddg.15033"},{"key":"2025022817345924465_j_znc-2024-0118_ref_009","doi-asserted-by":"crossref","unstructured":"Mascarenhas-Melo, F, Carvalho, A, Gon\u00e7alves, MBS, Paiva-Santos, AC, Veiga, F. Nanocarriers for the topical treatment of psoriasis-pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. Eur J Pharm Biopharm 2022;176:95\u2013107. https:\/\/doi.org\/10.1016\/j.ejpb.2022.05.012.","DOI":"10.1016\/j.ejpb.2022.05.012"},{"key":"2025022817345924465_j_znc-2024-0118_ref_010","unstructured":"Afifi, T, de Gannes, G, Huang, C, Zhou, Y. Topical therapies for psoriasis: evidence-based review. Can Fam Physician 2005;51:519\u201325."},{"key":"2025022817345924465_j_znc-2024-0118_ref_011","doi-asserted-by":"crossref","unstructured":"AlQassimi, S, AlBrashdi, S, Galadari, H, Hashim, MJ. Global burden of psoriasis\u2013comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol 2020;59:566\u201371. https:\/\/doi.org\/10.1111\/ijd.14864.","DOI":"10.1111\/ijd.14864"},{"key":"2025022817345924465_j_znc-2024-0118_ref_012","doi-asserted-by":"crossref","unstructured":"Tokuyama, M, Mabuchi, T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 2020;21. https:\/\/doi.org\/10.3390\/ijms21207488.","DOI":"10.3390\/ijms21207488"},{"key":"2025022817345924465_j_znc-2024-0118_ref_013","doi-asserted-by":"crossref","unstructured":"Yang, F, Lu, C, Wang, Y, Liu, H, Leng, X, Zeng, X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol 2023;42:1593\u2013605. https:\/\/doi.org\/10.1007\/s10067-023-06529-4.","DOI":"10.1007\/s10067-023-06529-4"},{"key":"2025022817345924465_j_znc-2024-0118_ref_014","doi-asserted-by":"crossref","unstructured":"Roskoski, JR. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res 2023;189:106642. https:\/\/doi.org\/10.1016\/j.phrs.2022.106642.","DOI":"10.1016\/j.phrs.2022.106642"},{"key":"2025022817345924465_j_znc-2024-0118_ref_015","doi-asserted-by":"crossref","unstructured":"Zhao, Y, Zhang, Y, Li, J, Zhang, N, Jin, Q, Qi, Y, et al.. Pathogenic sphingosine 1-phosphate pathway in psoriasis: a critical review of its pathogenic significance and potential as a therapeutic target. Lipids Health Dis 2023;22:52. https:\/\/doi.org\/10.1186\/s12944-023-01813-3.","DOI":"10.1186\/s12944-023-01813-3"},{"key":"2025022817345924465_j_znc-2024-0118_ref_016","doi-asserted-by":"crossref","unstructured":"Huang, Y, Mao, C-R, Lou, Y, Zhan, S, Chen, Z, Ding, W, et al.. Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective ROCK2 inhibitor for psoriasis treatment. J Med Chem 2023;66:15205\u201329. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01297.","DOI":"10.1021\/acs.jmedchem.3c01297"},{"key":"2025022817345924465_j_znc-2024-0118_ref_017","doi-asserted-by":"crossref","unstructured":"Yan, B, Liu, N, Li, J, Li, J, Zhu, W, Kuang, Y, et al.. The role of Langerhans cells in epidermal homeostasis and pathogenesis of psoriasis. J Cell Mol Med 2020;24:11646\u201355. https:\/\/doi.org\/10.1111\/jcmm.15834.","DOI":"10.1111\/jcmm.15834"},{"key":"2025022817345924465_j_znc-2024-0118_ref_018","doi-asserted-by":"crossref","unstructured":"Ni, X, Lai, Y. Keratinocyte: a trigger or an executor of psoriasis? J Leucocyte Biol 2020;108:485\u201391. https:\/\/doi.org\/10.1002\/jlb.5mr0120-439r.","DOI":"10.1002\/JLB.5MR0120-439R"},{"key":"2025022817345924465_j_znc-2024-0118_ref_019","doi-asserted-by":"crossref","unstructured":"Li, J, Hou, H, Zhou, L, Wang, J, Liang, J, Li, J, et al.. Increased angiogenesis and migration of dermal microvascular endothelial cells from patients with psoriasis. Exp Dermatol 2021;30:973\u201381. https:\/\/doi.org\/10.1111\/exd.14329.","DOI":"10.1111\/exd.14329"},{"key":"2025022817345924465_j_znc-2024-0118_ref_020","doi-asserted-by":"crossref","unstructured":"Wang, Y, Edelmayer, R, Wetter, J, Salte, K, Gauvin, D, Leys, L, et al.. Monocytes\/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation. Sci Rep 2019;9:5310. https:\/\/doi.org\/10.1038\/s41598-019-41655-7.","DOI":"10.1038\/s41598-019-41655-7"},{"key":"2025022817345924465_j_znc-2024-0118_ref_021","doi-asserted-by":"crossref","unstructured":"Dai, H, Adamopoulos, IE. Psoriatic arthritis under the influence of IFN\u03b3. Clin Immunol 2020;218:108513. https:\/\/doi.org\/10.1016\/j.clim.2020.108513.","DOI":"10.1016\/j.clim.2020.108513"},{"key":"2025022817345924465_j_znc-2024-0118_ref_022","doi-asserted-by":"crossref","unstructured":"Kiluk, P, Baran, A, Kaminski, T, Maciaszek, M, Flisiak, I. Decreased levels of vaspin and its potential association with cardiometabolic risk in patients with psoriasis: preliminary results. Adv Dermatol Allergol 2022;39:307\u201315. https:\/\/doi.org\/10.5114\/ada.2021.103383.","DOI":"10.5114\/ada.2021.103383"},{"key":"2025022817345924465_j_znc-2024-0118_ref_023","doi-asserted-by":"crossref","unstructured":"Saalbach, A, Tremel, J, Herbert, D, Schwede, K, Wandel, E, Schirmer, C, et al.. Anti-inflammatory action of keratinocyte-derived vaspin: relevance for the pathogenesis of psoriasis. Am J Pathol 2016;186:639\u201351. https:\/\/doi.org\/10.1016\/j.ajpath.2015.10.030.","DOI":"10.1016\/j.ajpath.2015.10.030"},{"key":"2025022817345924465_j_znc-2024-0118_ref_024","doi-asserted-by":"crossref","unstructured":"Zheng, Q-y, Liang, S-j, Xu, F, Li, G-q, Luo, N, Wu, S, et al.. C5a\/C5aR1 pathway is critical for the pathogenesis of psoriasis. Front Immunol 2019;10:1866. https:\/\/doi.org\/10.3389\/fimmu.2019.01866.","DOI":"10.3389\/fimmu.2019.01866"},{"key":"2025022817345924465_j_znc-2024-0118_ref_025","doi-asserted-by":"crossref","unstructured":"Shi, ZR, Tan, GZ, Cao, CX, Han, YF, Meng, Z, Man, XY, et al.. Decrease of galectin-3 in keratinocytes: a potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. J Autoimmun 2018;89:30\u201340. https:\/\/doi.org\/10.1016\/j.jaut.2017.11.002.","DOI":"10.1016\/j.jaut.2017.11.002"},{"key":"2025022817345924465_j_znc-2024-0118_ref_026","doi-asserted-by":"crossref","unstructured":"Ogawa, K, Okada, Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci 2020;99:2\u20138. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.05.008.","DOI":"10.1016\/j.jdermsci.2020.05.008"},{"key":"2025022817345924465_j_znc-2024-0118_ref_027","doi-asserted-by":"crossref","unstructured":"Singhvi, G, Manchanda, P, Krishna Rapalli, V, Kumar Dubey, S, Gupta, G, Dua, K. MicroRNAs as biological regulators in skin disorders. Biomed Pharmacother 2018;108:996\u20131004. https:\/\/doi.org\/10.1016\/j.biopha.2018.09.090.","DOI":"10.1016\/j.biopha.2018.09.090"},{"key":"2025022817345924465_j_znc-2024-0118_ref_028","doi-asserted-by":"crossref","unstructured":"Yin, F, Chan, JF, Zhu, Q, Fu, R, Chen, JH, Choi, GK, et al.. Development and in-use evaluation of a novel Luminex MicroPlex microsphere-based (TRIOL) assay for simultaneous identification of Mycobacterium tuberculosis and detection of first-line and second-line anti-tuberculous drug resistance in China. J Clin Pathol 2017;70:342\u20139. https:\/\/doi.org\/10.1136\/jclinpath-2016-203952.","DOI":"10.1136\/jclinpath-2016-203952"},{"key":"2025022817345924465_j_znc-2024-0118_ref_029","doi-asserted-by":"crossref","unstructured":"Shao, S, Cao, T, Jin, L, Li, B, Fang, H, Zhang, J, et al.. Increased lipocalin-2 contributes to the pathogenesis of psoriasis by modulating neutrophil chemotaxis and cytokine secretion. J Invest Dermatol 2016;136:1418\u201328. https:\/\/doi.org\/10.1016\/j.jid.2016.03.002.","DOI":"10.1016\/j.jid.2016.03.002"},{"key":"2025022817345924465_j_znc-2024-0118_ref_030","doi-asserted-by":"crossref","unstructured":"Zhong, H, Yang, H, Mao, Z, Chai, X, Li, S. Impact of moderate-to-severe psoriasis on quality of life in China: a qualitative study. Health Qual Life Outcome 2021;19:271. https:\/\/doi.org\/10.1186\/s12955-021-01902-w.","DOI":"10.1186\/s12955-021-01902-w"},{"key":"2025022817345924465_j_znc-2024-0118_ref_031","doi-asserted-by":"crossref","unstructured":"Aguayo, CP, Ruiz Carrascosa, JC, Molina Leyva, A. Type D personality is associated with poor quality of life, social performance, and psychological impairment in patients with moderate to severe psoriasis: a cross-sectional study of 130 patients. Indian J Dermatol Venereol Leprol 2020;86:375\u201381. 2020, https:\/\/doi.org\/10.4103\/ijdvl.ijdvl_114_19,","DOI":"10.4103\/ijdvl.IJDVL_114_19"},{"key":"2025022817345924465_j_znc-2024-0118_ref_032","doi-asserted-by":"crossref","unstructured":"Sumpton, D, Kelly, A, Tunnicliffe, DJ, Craig, JC, Hassett, G, Chessman, D, et al.. Patients\u2019 perspectives and experience of psoriasis and psoriatic arthritis: a systematic review and thematic synthesis of qualitative studies. Arthritis Care Res 2020;72:711\u201322. https:\/\/doi.org\/10.1002\/acr.23896.","DOI":"10.1002\/acr.23896"},{"key":"2025022817345924465_j_znc-2024-0118_ref_033","unstructured":"Al-Muhandis, K. An exploration of life with a chronic skin condition PhD dissertation. Royal Holloway, University of London; 2024."},{"key":"2025022817345924465_j_znc-2024-0118_ref_034","doi-asserted-by":"crossref","unstructured":"Olejnik-Wojciechowska, J, Boboryko, D, Bratborska, AW, Rusi\u0144ska, K, Ostrowski, P, Baranowska, M, et al.. The role of epigenetic factors in the pathogenesis of psoriasis. Int J Mol Sci 2024;25:3831. https:\/\/doi.org\/10.3390\/ijms25073831.","DOI":"10.3390\/ijms25073831"},{"key":"2025022817345924465_j_znc-2024-0118_ref_035","doi-asserted-by":"crossref","unstructured":"Kamata, M, Tada, Y. Crosstalk: keratinocytes and immune cells in psoriasis. Front Immunol 2023;14:1286344. https:\/\/doi.org\/10.3389\/fimmu.2023.1286344.","DOI":"10.3389\/fimmu.2023.1286344"},{"key":"2025022817345924465_j_znc-2024-0118_ref_036","doi-asserted-by":"crossref","unstructured":"Owczarek, W, Walecka, I, Nowakowska, A, Ciechanowicz, P, Reich, A, Lesiak, A, et al.. Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program \u201cTreatment of moderate and severe forms of plaque psoriasis (B. 47)\u201d of the National Health Fund in Poland. Adv Dermatol Allergol 2022;39:723\u20138. https:\/\/doi.org\/10.5114\/ada.2021.108442.","DOI":"10.5114\/ada.2021.108442"},{"key":"2025022817345924465_j_znc-2024-0118_ref_037","doi-asserted-by":"crossref","unstructured":"Owczarczyk-Saczonek, A, Purzycka-Bohdan, D, Nedoszytko, B, Reich, A, Szczerkowska-Dobosz, A, Bartosi\u0144ska, J, et al.. Pathogenesis of psoriasis in the \u201comic\u201d era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis in psoriasis. Adv Dermatol Allergol 2020;37:452\u201367. https:\/\/doi.org\/10.5114\/ada.2020.98284.","DOI":"10.5114\/ada.2020.98284"},{"key":"2025022817345924465_j_znc-2024-0118_ref_038","doi-asserted-by":"crossref","unstructured":"Dopytalska, K, Ciechanowicz, P, Wiszniewski, K, Szyma\u0144ska, E, Walecka, I. The role of epigenetic factors in psoriasis. Inter J Mol Sci 2021;22. https:\/\/doi.org\/10.3390\/ijms22179294.","DOI":"10.3390\/ijms22179294"},{"key":"2025022817345924465_j_znc-2024-0118_ref_039","doi-asserted-by":"crossref","unstructured":"Zhang, M, Bai, X, Cao, W, Ji, J, Wang, L, Yang, Y, et al.. The influence of corticosteroids, immunosuppressants and biologics on patients with inflammatory bowel diseases, psoriasis and rheumatic diseases in the era of COVID-19: a review of current evidence. Front Immunol 2021;12:677957. https:\/\/doi.org\/10.3389\/fimmu.2021.677957.","DOI":"10.3389\/fimmu.2021.677957"},{"key":"2025022817345924465_j_znc-2024-0118_ref_040","doi-asserted-by":"crossref","unstructured":"Bro\u017cyna, AA, Slominski, RM, Nedoszytko, B, Zmijewski, MA, Slominski, AT. Vitamin D signaling in psoriasis: pathogenesis and therapy. Int J Mol Sci 2022;23:8575. https:\/\/doi.org\/10.3390\/ijms23158575.","DOI":"10.3390\/ijms23158575"},{"key":"2025022817345924465_j_znc-2024-0118_ref_041","doi-asserted-by":"crossref","unstructured":"Coates, LC, Merola, JF, Grieb, SM, Mease, PJ, Duffin, KC. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl 2020;96:31\u20135. https:\/\/doi.org\/10.3899\/jrheum.200124.","DOI":"10.3899\/jrheum.200124"},{"key":"2025022817345924465_j_znc-2024-0118_ref_042","doi-asserted-by":"crossref","unstructured":"Lebwohl, M, Tha\u00e7i, D, Warren, RB. Addressing challenges associated with long\u2010term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol 2021;35:35\u201341. https:\/\/doi.org\/10.1111\/jdv.17053.","DOI":"10.1111\/jdv.17053"},{"key":"2025022817345924465_j_znc-2024-0118_ref_043","doi-asserted-by":"crossref","unstructured":"Gorelick, J, Shrom, D, Sikand, K, Renda, L, Burge, R, Dworkin, C, et al.. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther 2019;9:785\u201397. https:\/\/doi.org\/10.1007\/s13555-019-00334-1.","DOI":"10.1007\/s13555-019-00334-1"},{"key":"2025022817345924465_j_znc-2024-0118_ref_044","unstructured":"Feldman, SR, Goffe, B, Rice, G, Mitchell, M, Kaur, M, Robertson, D, et al.. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits 2016;9:504."},{"key":"2025022817345924465_j_znc-2024-0118_ref_045","unstructured":"Cohen, M, Morrow, T, Penna, P. Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies. Am J Manag Care 2006;12:S24\u201337."},{"key":"2025022817345924465_j_znc-2024-0118_ref_046","doi-asserted-by":"crossref","unstructured":"Wollina, U, Tirant, M, Vojvodic, A, Lotti, T. Treatment of psoriasis: novel approaches to topical delivery. Open Access Maced J Med Sci 2019;7:3018\u201325. https:\/\/doi.org\/10.3889\/oamjms.2019.414.","DOI":"10.3889\/oamjms.2019.414"},{"key":"2025022817345924465_j_znc-2024-0118_ref_047","doi-asserted-by":"crossref","unstructured":"Dadwal, A, Mishra, N, Narang, KR. Novel topical nanocarriers for treatment of psoriasis: an overview. Curr Pharmaceut Des 2018;24:3934\u201350. https:\/\/doi.org\/10.2174\/1381612824666181102151507.","DOI":"10.2174\/1381612824666181102151507"},{"key":"2025022817345924465_j_znc-2024-0118_ref_048","doi-asserted-by":"crossref","unstructured":"Wang, S-H, Wang, J, Lin, Y-S, Tung, T-H, Chi, C-C. Increased risk for incident thyroid diseases in people with psoriatic disease: a cohort study. J Am Acad Dermatol 2019;80:1006\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.049.","DOI":"10.1016\/j.jaad.2018.11.049"},{"key":"2025022817345924465_j_znc-2024-0118_ref_049","doi-asserted-by":"crossref","unstructured":"Tambe, VS, Nautiyal, A, Wairkar, S. Topical lipid nanocarriers for management of psoriasis-an overview. J Drug Deliv Sci Technol 2021;64:102671. https:\/\/doi.org\/10.1016\/j.jddst.2021.102671.","DOI":"10.1016\/j.jddst.2021.102671"},{"key":"2025022817345924465_j_znc-2024-0118_ref_050","doi-asserted-by":"crossref","unstructured":"Parveen, N, Sheikh, A, Abourehab, MAS, Karwasra, R, Singh, S, Kesharwani, P. Self-nanoemulsifying drug delivery system for pancreatic cancer. Eur Polym J 2023;190:111993. https:\/\/doi.org\/10.1016\/j.eurpolymj.2023.111993.","DOI":"10.1016\/j.eurpolymj.2023.111993"},{"key":"2025022817345924465_j_znc-2024-0118_ref_051","doi-asserted-by":"crossref","unstructured":"Wilczewska, AZ, Niemirowicz, K, Markiewicz, KH, Car, H. Nanoparticles as drug delivery systems. Pharmacol Rep 2012;64:1020\u201337. https:\/\/doi.org\/10.1016\/s1734-1140(12)70901-5.","DOI":"10.1016\/S1734-1140(12)70901-5"},{"key":"2025022817345924465_j_znc-2024-0118_ref_052","doi-asserted-by":"crossref","unstructured":"Abucayon, EG, Rao, M, Matyas, GR, Alving, CR. QS21-Initiated fusion of liposomal small unilamellar vesicles to form ALFQ results in concentration of most of the monophosphoryl lipid A, QS21, and cholesterol in giant unilamellar vesicles. Pharmaceutics 2023;15:2212. https:\/\/doi.org\/10.3390\/pharmaceutics15092212.","DOI":"10.3390\/pharmaceutics15092212"},{"key":"2025022817345924465_j_znc-2024-0118_ref_053","doi-asserted-by":"crossref","unstructured":"Lou, G, Anderluzzi, G, Woods, S, Roberts, CW, Perrie, Y. A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: formulation, cellular uptake and biodistribution investigations. Eur J Pharm Biopharm 2019;143:51\u201360. https:\/\/doi.org\/10.1016\/j.ejpb.2019.08.013.","DOI":"10.1016\/j.ejpb.2019.08.013"},{"key":"2025022817345924465_j_znc-2024-0118_ref_054","doi-asserted-by":"crossref","unstructured":"Hsieh, A-H, Corti, DS, Franses, EI. Rayleigh and Rayleigh-Debye-Gans light scattering intensities and spetroturbidimetry of dispersions of unilamellar vesicles and multilamellar liposomes. J Colloid Interface Sci 2020;578:471\u201383. https:\/\/doi.org\/10.1016\/j.jcis.2020.05.085.","DOI":"10.1016\/j.jcis.2020.05.085"},{"key":"2025022817345924465_j_znc-2024-0118_ref_055","doi-asserted-by":"crossref","unstructured":"Gorain, B, Al-Dhubiab, BE, Nair, A, Kesharwani, P, Pandey, M, Choudhury, H. Multivesicular liposome: a lipid-based drug delivery system for efficient drug delivery. Curr Pharmaceut Des 2021;27:4404\u201315. https:\/\/doi.org\/10.2174\/18734286mte3cntq0z.","DOI":"10.2174\/1381612827666210830095941"},{"key":"2025022817345924465_j_znc-2024-0118_ref_056","doi-asserted-by":"crossref","unstructured":"Maja, L, \u017deljko, K, Mateja, P. Sustainable technologies for liposome preparation. J Supercrit Fluids 2020;165:104984. https:\/\/doi.org\/10.1016\/j.supflu.2020.104984.","DOI":"10.1016\/j.supflu.2020.104984"},{"key":"2025022817345924465_j_znc-2024-0118_ref_057","doi-asserted-by":"crossref","unstructured":"Ong, SG, Ming, LC, Lee, KS, Yuen, KH. Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics 2016;8. https:\/\/doi.org\/10.3390\/pharmaceutics8030025.","DOI":"10.3390\/pharmaceutics8030025"},{"key":"2025022817345924465_j_znc-2024-0118_ref_058","doi-asserted-by":"crossref","unstructured":"Kelly, C, Jefferies, C, Cryan, S-A. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011;2011. https:\/\/doi.org\/10.1155\/2011\/727241.","DOI":"10.1155\/2011\/727241"},{"key":"2025022817345924465_j_znc-2024-0118_ref_059","doi-asserted-by":"crossref","unstructured":"Caracciolo, G, Pozzi, D, Caminiti, R, Amenitsch, H. Lipid mixing upon deoxyribonucleic acid-induced liposomes fusion investigated by synchrotron small-angle x-ray scattering. Appl Phys Lett 2005;87. https:\/\/doi.org\/10.1063\/1.2058202.","DOI":"10.1063\/1.2058202"},{"key":"2025022817345924465_j_znc-2024-0118_ref_060","doi-asserted-by":"crossref","unstructured":"Storm, G, Belliot, SO, Daemen, T, Lasic, DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995;17:31\u201348. https:\/\/doi.org\/10.1016\/0169-409x(95)00039-a.","DOI":"10.1016\/0169-409X(95)00039-A"},{"key":"2025022817345924465_j_znc-2024-0118_ref_061","doi-asserted-by":"crossref","unstructured":"Bozzuto, G, Molinari, A. Liposomes as nanomedical devices. Int J Nanomed 2015;10:975\u201399. https:\/\/doi.org\/10.2147\/ijn.s68861.","DOI":"10.2147\/IJN.S68861"},{"key":"2025022817345924465_j_znc-2024-0118_ref_062","doi-asserted-by":"crossref","unstructured":"Agrawal, M, Ajazuddin, Tripathi, DK, Saraf, S, Saraf, S, Antimisiaris, SG, et al.. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer\u2019s disease. J Contr Release 2017;260:61\u201377. https:\/\/doi.org\/10.1016\/j.jconrel.2017.05.019.","DOI":"10.1016\/j.jconrel.2017.05.019"},{"key":"2025022817345924465_j_znc-2024-0118_ref_063","doi-asserted-by":"crossref","unstructured":"Ramanunny, AK, Wadhwa, S, Gulati, M, Singh, SK, Kapoor, B, Dureja, H, et al.. Nanocarriers for treatment of dermatological diseases: principle, perspective and practices. Eur J Pharmacol 2021;890:173691. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173691.","DOI":"10.1016\/j.ejphar.2020.173691"},{"key":"2025022817345924465_j_znc-2024-0118_ref_064","doi-asserted-by":"crossref","unstructured":"Chen, Y, Feng, X, Meng, S. Site-specific drug delivery in the skin for the localized treatment of skin diseases. Expet Opin Drug Deliv 2019;16:847\u201367. https:\/\/doi.org\/10.1080\/17425247.2019.1645119.","DOI":"10.1080\/17425247.2019.1645119"},{"key":"2025022817345924465_j_znc-2024-0118_ref_065","doi-asserted-by":"crossref","unstructured":"Ibaraki, H, Kanazawa, T, Oogi, C, Takashima, Y, Seta, Y. Effects of surface charge and flexibility of liposomes on dermal drug delivery. J Drug Deliv Sci Technol 2019;50:155\u201362. https:\/\/doi.org\/10.1016\/j.jddst.2019.01.028.","DOI":"10.1016\/j.jddst.2019.01.028"},{"key":"2025022817345924465_j_znc-2024-0118_ref_066","doi-asserted-by":"crossref","unstructured":"Jenabikordi, K, Zadeh, BSM, Rezaie, A. Co-encapsulation of metformin and ginger into the liposomes: in\u00a0vitro characterization and in\u00a0vivo anti-psoriasis evaluation. Drug Dev Ind Pharm 2021;47:1447\u201358. https:\/\/doi.org\/10.1080\/03639045.2021.2001488.","DOI":"10.1080\/03639045.2021.2001488"},{"key":"2025022817345924465_j_znc-2024-0118_ref_067","doi-asserted-by":"crossref","unstructured":"Sguizzato, M, Esposito, E, Cortesi, R. Lipid-based nanosystems as a tool to overcome skin barrier. Int J Mol Sci 2021;22:8319. https:\/\/doi.org\/10.3390\/ijms22158319.","DOI":"10.3390\/ijms22158319"},{"key":"2025022817345924465_j_znc-2024-0118_ref_068","doi-asserted-by":"crossref","unstructured":"Walunj, M, Doppalapudi, S, Bulbake, U, Khan, W. Preparation, characterization, and in\u00a0vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis. J Liposome Res 2020;30:68\u201379. https:\/\/doi.org\/10.1080\/08982104.2019.1593449.","DOI":"10.1080\/08982104.2019.1593449"},{"key":"2025022817345924465_j_znc-2024-0118_ref_069","doi-asserted-by":"crossref","unstructured":"Qu, F, Sun, Y, Bi, D, Peng, S, Li, M, Liu, H, et al.. Regulating size and charge of liposomes in microneedles to enhance intracellular drug delivery efficiency in skin for psoriasis therapy. Adv Healthcare Mater 2023;12:2302314. https:\/\/doi.org\/10.1002\/adhm.202302314.","DOI":"10.1002\/adhm.202302314"},{"key":"2025022817345924465_j_znc-2024-0118_ref_070","doi-asserted-by":"crossref","unstructured":"Bahadur, S, Sharma, M. Liposome based drug delivery for the management of psoriasis-A comprehensive review. Curr Pharmaceut Biotechnol 2023;24:1383\u201396. https:\/\/doi.org\/10.2174\/1389201024666221213144228.","DOI":"10.2174\/1389201024666221213144228"},{"key":"2025022817345924465_j_znc-2024-0118_ref_071","doi-asserted-by":"crossref","unstructured":"Pradhan, M, Alexander, A, Singh, MR, Singh, D, Saraf, S, Saraf, S, et al.. Understanding the prospective of nano-formulations towards the treatment of psoriasis. Biomed Pharmacother 2018;107:447\u201363. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.156.","DOI":"10.1016\/j.biopha.2018.07.156"},{"key":"2025022817345924465_j_znc-2024-0118_ref_072","doi-asserted-by":"crossref","unstructured":"Rapalli, VK, Waghule, T, Gorantla, S, Dubey, SK, Saha, RN, Singhvi, G. Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems. Drug Discov Today 2020;25:2212\u201326. https:\/\/doi.org\/10.1016\/j.drudis.2020.09.023.","DOI":"10.1016\/j.drudis.2020.09.023"},{"key":"2025022817345924465_j_znc-2024-0118_ref_073","doi-asserted-by":"crossref","unstructured":"Kubackova, J, Zbytovska, J, Holas, O. Nanomaterials for direct and indirect immunomodulation: a review of applications. Eur J Pharmaceut Sci 2020;142:105139. https:\/\/doi.org\/10.1016\/j.ejps.2019.105139.","DOI":"10.1016\/j.ejps.2019.105139"},{"key":"2025022817345924465_j_znc-2024-0118_ref_074","doi-asserted-by":"crossref","unstructured":"Gomes, GS, Frank, LA, Contri, RV, Longhi, MS, Pohlmann, AR, Guterres, SS. Nanotechnology-based alternatives for the topical delivery of immunosuppressive agents in psoriasis. Int J Pharm 2023;631:122535. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122535.","DOI":"10.1016\/j.ijpharm.2022.122535"},{"key":"2025022817345924465_j_znc-2024-0118_ref_075","doi-asserted-by":"crossref","unstructured":"Lin, Z, Xi, L, Chen, S, Tao, J, Wang, Y, Chen, X, et al.. Uptake and trafficking of different sized PLGA nanoparticles by dendritic cells in imiquimod-induced psoriasis-like mice model. Acta Pharm Sin B 2021;11:1047\u201355. https:\/\/doi.org\/10.1016\/j.apsb.2020.11.008.","DOI":"10.1016\/j.apsb.2020.11.008"},{"key":"2025022817345924465_j_znc-2024-0118_ref_076","doi-asserted-by":"crossref","unstructured":"Jyothi, SL, Krishna, KL, Shirin, VKA, Sankar, R, Pramod, K, Gangadharappa, HV. Drug delivery systems for the treatment of psoriasis: current status and prospects. J Drug Deliv Sci Technol 2021;62:102364. https:\/\/doi.org\/10.1016\/j.jddst.2021.102364.","DOI":"10.1016\/j.jddst.2021.102364"},{"key":"2025022817345924465_j_znc-2024-0118_ref_077","doi-asserted-by":"crossref","unstructured":"Maione-Silva, L, de Castro, EG, Nascimento, TL, Cintra, ER, Moreira, LC, Cintra, BAS, et al.. Ascorbic acid encapsulated into negatively charged liposomes exhibits increased skin permeation, retention and enhances collagen synthesis by fibroblasts. Sci Rep 2019;9:522. https:\/\/doi.org\/10.1038\/s41598-018-36682-9.","DOI":"10.1038\/s41598-018-36682-9"},{"key":"2025022817345924465_j_znc-2024-0118_ref_078","doi-asserted-by":"crossref","unstructured":"Riaz, MK, Riaz, MA, Zhang, X, Lin, C, Wong, KH, Chen, X, et al.. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci 2018;19:195. https:\/\/doi.org\/10.3390\/ijms19010195.","DOI":"10.3390\/ijms19010195"},{"key":"2025022817345924465_j_znc-2024-0118_ref_079","doi-asserted-by":"crossref","unstructured":"Saleem, S, Iqubal, MK, Garg, S, Ali, J, Baboota, S. Trends in nanotechnology-based delivery systems for dermal targeting of drugs: an enticing approach to offset psoriasis. Expet Opin Drug Deliv 2020;17:817\u201338. https:\/\/doi.org\/10.1080\/17425247.2020.1758665.","DOI":"10.1080\/17425247.2020.1758665"},{"key":"2025022817345924465_j_znc-2024-0118_ref_080","doi-asserted-by":"crossref","unstructured":"Biswasroy, P, Pradhan, D, Kar, B, Ghosh, G, Rath, G. Recent advancement in topical nanocarriers for the treatment of psoriasis. AAPS PharmSciTech 2021;22:164. https:\/\/doi.org\/10.1208\/s12249-021-02057-z.","DOI":"10.1208\/s12249-021-02057-z"},{"key":"2025022817345924465_j_znc-2024-0118_ref_081","doi-asserted-by":"crossref","unstructured":"Singh, A, Maheshwari, S. Formulation and evaluation of ferulic acid and oleic acid containing liposomal gel for skin nourishment. Intell Pharm 2023. https:\/\/doi.org\/10.1016\/j.ipha.2023.10.014.","DOI":"10.1016\/j.ipha.2023.10.014"},{"key":"2025022817345924465_j_znc-2024-0118_ref_082","doi-asserted-by":"crossref","unstructured":"Doppalapudi, S, Jain, A, Chopra, DK, Khan, W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharmaceut Sci: Off J Eur Fed Pharmaceut Sci 2017;96:515\u201329. https:\/\/doi.org\/10.1016\/j.ejps.2016.10.025.","DOI":"10.1016\/j.ejps.2016.10.025"},{"key":"2025022817345924465_j_znc-2024-0118_ref_083","doi-asserted-by":"crossref","unstructured":"Jain, H, Geetanjali, D, Dalvi, H, Bhat, A, Godugu, C, Srivastava, S. Liposome mediated topical delivery of Ibrutinib and Curcumin as a synergistic approach to combat imiquimod induced psoriasis. J Drug Deliv Sci Technol 2022;68:103103. https:\/\/doi.org\/10.1016\/j.jddst.2022.103103.","DOI":"10.1016\/j.jddst.2022.103103"},{"key":"2025022817345924465_j_znc-2024-0118_ref_084","doi-asserted-by":"crossref","unstructured":"Yadav, K, Singh, D, Singh, MR, Pradhan, M. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis. Med Hypotheses 2020;145:110322. https:\/\/doi.org\/10.1016\/j.mehy.2020.110322.","DOI":"10.1016\/j.mehy.2020.110322"},{"key":"2025022817345924465_j_znc-2024-0118_ref_085","doi-asserted-by":"crossref","unstructured":"Srisuk, P, Thongnopnua, P, Raktanonchai, U, Kanokpanont, S. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in\u00a0vitro transepidermal delivery targeting psoriasis treatment. Int J Pharm 2012;427:426\u201334. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.01.045.","DOI":"10.1016\/j.ijpharm.2012.01.045"},{"key":"2025022817345924465_j_znc-2024-0118_ref_086","doi-asserted-by":"crossref","unstructured":"Yu, F, Zhang, Y, Yang, C, Li, F, Qiu, B, Ding, W. Enhanced transdermal efficiency of curcumin-loaded peptide-modified liposomes for highly effective antipsoriatic therapy. J Mater Chem B 2021;9:4846\u201356. https:\/\/doi.org\/10.1039\/d1tb00557j.","DOI":"10.1039\/D1TB00557J"},{"key":"2025022817345924465_j_znc-2024-0118_ref_087","doi-asserted-by":"crossref","unstructured":"Javia, A, Misra, A, Thakkar, H. Liposomes encapsulating novel antimicrobial peptide Omiganan: characterization and its pharmacodynamic evaluation in atopic dermatitis and psoriasis mice model. Int J Pharm 2022;624:122045. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122045.","DOI":"10.1016\/j.ijpharm.2022.122045"},{"key":"2025022817345924465_j_znc-2024-0118_ref_088","doi-asserted-by":"crossref","unstructured":"Bahramizadeh, M, Bahramizadeh, M, Kiafar, B, Jafarian, AH, Nikpoor, AR, Hatamipour, M, et al.. Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model. Int J Pharm 2019;569:118623. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118623.","DOI":"10.1016\/j.ijpharm.2019.118623"},{"key":"2025022817345924465_j_znc-2024-0118_ref_089","doi-asserted-by":"crossref","unstructured":"Sadarani, B, Majumdar, A, Paradkar, S, Mathur, A, Sachdev, S, Mohanty, B, et al.. Enhanced skin permeation of Methotrexate from penetration enhancer containing vesicles: in\u00a0vitro optimization and in\u00a0vivo evaluation. Biomed Pharmacother 2019;114:108770. https:\/\/doi.org\/10.1016\/j.biopha.2019.108770.","DOI":"10.1016\/j.biopha.2019.108770"},{"key":"2025022817345924465_j_znc-2024-0118_ref_090","doi-asserted-by":"crossref","unstructured":"Pukale, SS, Sahel, DK, Mittal, A, Chitkara, D. Coenzyme Q10 loaded lipid-polymer hybrid nanoparticles in gel for the treatment of psoriasis like skin condition. J Drug Deliv Sci Technol 2022;76:103672. https:\/\/doi.org\/10.1016\/j.jddst.2022.103672.","DOI":"10.1016\/j.jddst.2022.103672"},{"key":"2025022817345924465_j_znc-2024-0118_ref_091","doi-asserted-by":"crossref","unstructured":"Saka, R, Jain, H, Kommineni, N, Chella, N, Khan, W. Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB\/c mice. J Drug Deliv Sci Technol 2020;58:101691. https:\/\/doi.org\/10.1016\/j.jddst.2020.101691.","DOI":"10.1016\/j.jddst.2020.101691"},{"key":"2025022817345924465_j_znc-2024-0118_ref_092","doi-asserted-by":"crossref","unstructured":"Chen, J, Ma, Y, Tao, Y, Zhao, X, Xiong, Y, Chen, Z, et al.. Formulation and evaluation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity. J Liposome Res 2021;31:130\u201344. https:\/\/doi.org\/10.1080\/08982104.2020.1748646.","DOI":"10.1080\/08982104.2020.1748646"},{"key":"2025022817345924465_j_znc-2024-0118_ref_093","unstructured":"Bhatia, A, Kumar, R, Katare, OP. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation. J Pharm Pharm Sci 2004;7:252\u20139."},{"key":"2025022817345924465_j_znc-2024-0118_ref_094","doi-asserted-by":"crossref","unstructured":"Lee, H-J, Kim, M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci 2023;24:13313. https:\/\/doi.org\/10.3390\/ijms241713313.","DOI":"10.3390\/ijms241713313"},{"key":"2025022817345924465_j_znc-2024-0118_ref_095","doi-asserted-by":"crossref","unstructured":"Singh, S, Awasthi, R. Breakthroughs and bottlenecks of psoriasis therapy: emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery. J Drug Deliv Sci Technol 2023:104548. https:\/\/doi.org\/10.1016\/j.jddst.2023.104548.","DOI":"10.1016\/j.jddst.2023.104548"},{"key":"2025022817345924465_j_znc-2024-0118_ref_096","doi-asserted-by":"crossref","unstructured":"Chen, G, Li, D, Jin, Y, Zhang, W, Teng, L, Bunt, C, et al.. Deformable liposomes by reverse-phase evaporation method for an enhanced skin delivery of (+)-catechin. Drug Dev Ind Pharm 2014;40:260\u20135. https:\/\/doi.org\/10.3109\/03639045.2012.756512.","DOI":"10.3109\/03639045.2012.756512"},{"key":"2025022817345924465_j_znc-2024-0118_ref_097","doi-asserted-by":"crossref","unstructured":"Bochicchio, S, Dalmoro, A, De Simone, V, Bertoncin, P, Lamberti, G, Barba, AA. Simil-microfluidic nanotechnology in manufacturing of liposomes as hydrophobic antioxidants skin release systems. Cosmetics 2020;7:22. https:\/\/doi.org\/10.3390\/cosmetics7020022.","DOI":"10.3390\/cosmetics7020022"},{"key":"2025022817345924465_j_znc-2024-0118_ref_098","doi-asserted-by":"crossref","unstructured":"Doppalapudi, S, Jain, A, Chopra, DK, Khan, W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharmaceut Sci 2017;96:515\u201329. https:\/\/doi.org\/10.1016\/j.ejps.2016.10.025.","DOI":"10.1016\/j.ejps.2016.10.025"},{"key":"2025022817345924465_j_znc-2024-0118_ref_099","doi-asserted-by":"crossref","unstructured":"Verma, DD, Verma, S, Blume, G, Fahr, A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 2003;258:141\u201351. https:\/\/doi.org\/10.1016\/s0378-5173(03)00183-2.","DOI":"10.1016\/S0378-5173(03)00183-2"},{"key":"2025022817345924465_j_znc-2024-0118_ref_100","doi-asserted-by":"crossref","unstructured":"Dubey, S, Sharma, R, Mody, N, Vyas, SP. Novel carriers and approaches: insight for psoriasis management. In: Nanostructures for novel therapy. Elsevier; 2017:657\u201384 pp.","DOI":"10.1016\/B978-0-323-46142-9.00024-4"},{"key":"2025022817345924465_j_znc-2024-0118_ref_101","doi-asserted-by":"crossref","unstructured":"Alam, M, Rizwanullah, M, Mir, SR, Amin, S. Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis. OpenNano 2023;10:100123. https:\/\/doi.org\/10.1016\/j.onano.2023.100123.","DOI":"10.1016\/j.onano.2023.100123"},{"key":"2025022817345924465_j_znc-2024-0118_ref_102","doi-asserted-by":"crossref","unstructured":"Nordin, UUM, Ahmad, N, Salim, N, Yusof, NSM. Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Adv 2021;11:29080\u2013101. https:\/\/doi.org\/10.1039\/d1ra06087b.","DOI":"10.1039\/D1RA06087B"},{"key":"2025022817345924465_j_znc-2024-0118_ref_103","doi-asserted-by":"crossref","unstructured":"Huang, C, Gou, K, Yue, X, Zhao, S, Zeng, R, Qu, Y, et al.. A novel hyaluronic acid-based dissolving microneedle patch loaded with ginsenoside Rg3 liposome for effectively alleviate psoriasis. Mater Des 2022;224:111363. https:\/\/doi.org\/10.1016\/j.matdes.2022.111363.","DOI":"10.1016\/j.matdes.2022.111363"},{"key":"2025022817345924465_j_znc-2024-0118_ref_104","doi-asserted-by":"crossref","unstructured":"Li, H, Zuo, J, Tang, W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol 2018;9:1048. [Epub 2018\/11\/06] https:\/\/doi.org\/10.3389\/fphar.2018.01048.","DOI":"10.3389\/fphar.2018.01048"},{"key":"2025022817345924465_j_znc-2024-0118_ref_105","doi-asserted-by":"crossref","unstructured":"Rapalli, VK, Singhvi, G, Dubey, SK, Gupta, G, Chellappan, DK, Dua, K. Emerging landscape in psoriasis management: from topical application to targeting biomolecules. Biomed Pharmacother 2018;106:707\u201313. https:\/\/doi.org\/10.1016\/j.biopha.2018.06.136.","DOI":"10.1016\/j.biopha.2018.06.136"},{"key":"2025022817345924465_j_znc-2024-0118_ref_106","doi-asserted-by":"crossref","unstructured":"Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, O\u2019Shea, JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843\u201362. https:\/\/doi.org\/10.1038\/nrd.2017.201.","DOI":"10.1038\/nrd.2017.201"},{"key":"2025022817345924465_j_znc-2024-0118_ref_107","doi-asserted-by":"crossref","unstructured":"Jeon, C, Sekhon, S, Yan, D, Afifi, L, Nakamura, M, Bhutani, T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccines Immunother 2017;13:2247\u201359. https:\/\/doi.org\/10.1080\/21645515.2017.1356498.","DOI":"10.1080\/21645515.2017.1356498"},{"key":"2025022817345924465_j_znc-2024-0118_ref_108","doi-asserted-by":"crossref","unstructured":"Korkmaz, E, Falo, LD. Spherical nucleic acids as emerging topical therapeutics: a focus on psoriasis. J Invest Dermatol 2020;140:278\u201381. https:\/\/doi.org\/10.1016\/j.jid.2019.07.683.","DOI":"10.1016\/j.jid.2019.07.683"},{"key":"2025022817345924465_j_znc-2024-0118_ref_109","doi-asserted-by":"crossref","unstructured":"Guillot, AJ, Mart\u00ednez-Navarrete, M, Garrigues, TM, Melero, A. Skin drug delivery using lipid vesicles: a starting guideline for their development. J Contr Release 2023;355:624\u201354. https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.006.","DOI":"10.1016\/j.jconrel.2023.02.006"},{"key":"2025022817345924465_j_znc-2024-0118_ref_110","doi-asserted-by":"crossref","unstructured":"Yuan, L, Pan, M, Shi, K, Hu, D, Li, Y, Chen, Y, et al.. Nanocarriers for promoting skin delivery of therapeutic agents. Appl Mater Today 2022;27:101438. https:\/\/doi.org\/10.1016\/j.apmt.2022.101438.","DOI":"10.1016\/j.apmt.2022.101438"},{"key":"2025022817345924465_j_znc-2024-0118_ref_111","doi-asserted-by":"crossref","unstructured":"Antimisiaris, SG, Marazioti, A, Kannavou, M, Natsaridis, E, Gkartziou, F, Kogkos, G, et al.. Overcoming barriers by local drug delivery with liposomes. Adv Drug Deliv Rev 2021;174:53\u201386. https:\/\/doi.org\/10.1016\/j.addr.2021.01.019.","DOI":"10.1016\/j.addr.2021.01.019"},{"key":"2025022817345924465_j_znc-2024-0118_ref_112","doi-asserted-by":"crossref","unstructured":"Souto, EB, Macedo, AS, Dias-Ferreira, J, Cano, A, Zieli\u0144ska, A, Matos, CM. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs). Int J Mol Sci 2021;22:9743. https:\/\/doi.org\/10.3390\/ijms22189743.","DOI":"10.3390\/ijms22189743"},{"key":"2025022817345924465_j_znc-2024-0118_ref_113","doi-asserted-by":"crossref","unstructured":"Knudsen, N\u00d8, R\u00f8nholt, S, Salte, RD, Jorgensen, L, Thormann, T, Basse, LH, et al.. Calcipotriol delivery into the skin with PEGylated liposomes. Eur J Pharm Biopharm 2012;81:532\u20139. https:\/\/doi.org\/10.1016\/j.ejpb.2012.04.005.","DOI":"10.1016\/j.ejpb.2012.04.005"},{"key":"2025022817345924465_j_znc-2024-0118_ref_114","doi-asserted-by":"crossref","unstructured":"Mezei, M, Gulasekharam, V. Liposomes\u00a0\u2013 a selective drug delivery system for the topical route of administration: gel dosage form. J Pharm Pharmacol 1982;34:473\u20134. https:\/\/doi.org\/10.1111\/j.2042-7158.1982.tb04767.x.","DOI":"10.1111\/j.2042-7158.1982.tb04767.x"},{"key":"2025022817345924465_j_znc-2024-0118_ref_115","unstructured":"Lai, RC, Yeo, RWY, Zhang, B, Koh, M, Tan, S. Topical application of Yolk lecithin liposomes reinforces skin barrier function against chemical agents such as psoriasis-inducing IMQ and alleviates disease phenotype. Clin Exp Dermatol Ther 2018;2018:1\u201310."},{"key":"2025022817345924465_j_znc-2024-0118_ref_116","doi-asserted-by":"crossref","unstructured":"Wang, W, Shu, G-f, Lu, K-j, Xu, X-l, Sun, M-c, Qi, J, et al.. Flexible liposomal gel dual-loaded with all-trans retinoic acid and betamethasone for enhanced therapeutic efficiency of psoriasis. J Nanobiotechnol 2020;18:1\u201314. https:\/\/doi.org\/10.1186\/s12951-020-00635-0.","DOI":"10.1186\/s12951-020-00635-0"},{"key":"2025022817345924465_j_znc-2024-0118_ref_117","doi-asserted-by":"crossref","unstructured":"Liu, L, Ji, F, Zhao, Y, Hai, X. Arsenic trioxide liposome gels for the treatment of psoriasis in mice. J Liposome Res 2023:1\u201310. https:\/\/doi.org\/10.1080\/08982104.2023.2251054.","DOI":"10.1080\/08982104.2023.2251054"},{"key":"2025022817345924465_j_znc-2024-0118_ref_118","doi-asserted-by":"crossref","unstructured":"Fathalla, D, Youssef, EMK, Soliman, GM. Liposomal and ethosomal gels for the topical delivery of anthralin: preparation, comparative evaluation and clinical assessment in psoriatic patients. Pharmaceutics 2020;12. https:\/\/doi.org\/10.3390\/pharmaceutics12050446.","DOI":"10.3390\/pharmaceutics12050446"},{"key":"2025022817345924465_j_znc-2024-0118_ref_119","doi-asserted-by":"crossref","unstructured":"Kumar, R, Dogra, S, Amarji, B, Singh, B, Kumar, S, Sharma, et al.. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatology 2016;152:807\u201315. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0859.","DOI":"10.1001\/jamadermatol.2016.0859"},{"key":"2025022817345924465_j_znc-2024-0118_ref_120","doi-asserted-by":"crossref","unstructured":"Pierre, MBR, dos Santos Miranda Costa, I. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch Dermatol Res 2011;303:607\u201321. https:\/\/doi.org\/10.1007\/s00403-011-1166-4.","DOI":"10.1007\/s00403-011-1166-4"},{"key":"2025022817345924465_j_znc-2024-0118_ref_121","doi-asserted-by":"crossref","unstructured":"Boche\u0144ska, K, Smoli\u0144ska, E, Moskot, M, Jak\u00f3bkiewicz-Banecka, J, Gabig-Cimi\u0144ska, M. Models in the research process of psoriasis. Int J Mol Sci 2017;18:2514. https:\/\/doi.org\/10.3390\/ijms18122514.","DOI":"10.3390\/ijms18122514"}],"container-title":["Zeitschrift f\u00fcr Naturforschung C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/znc-2024-0118\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/znc-2024-0118\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T17:36:55Z","timestamp":1740764215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/znc-2024-0118\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":121,"journal-issue":{"issue":"3-4","published-online":{"date-parts":[[2025,2,28]]},"published-print":{"date-parts":[[2025,3,26]]}},"alternative-id":["10.1515\/znc-2024-0118"],"URL":"https:\/\/doi.org\/10.1515\/znc-2024-0118","relation":{},"ISSN":["0939-5075","1865-7125"],"issn-type":[{"value":"0939-5075","type":"print"},{"value":"1865-7125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}